Author

Nigel Ray

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Daniel FernándeziD· 1 shared Jacqueline A. CarozzaiD· 1 shared Jacqueline S. Papkoff· 1 shared Jan J. Scicinski· 1 shared Lingyin LiiD· 1 shared Neil A. Verity· 1 shared Rachel E. Mardjuki· 1 shared Randolph M. Johnson· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Daniel FernándezORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

ENPP1 inhibitor with ultralong drug-target residence time as an innate immune checkpoint blockade cancer therapy

Randolph M. Johnson, Songnan Wang, Jacqueline A. Carozza, Daniel Fernández, Jan J. Scicinski, Neil A. Verity, Rachel E. Mardjuki, Xujun Cao, Jacqueline S. Papkoff, Nigel Ray, Lingyin Li

A small molecule blocks ENPP1, reviving immune attack on tumors and enhancing immune therapy with minimal side effects in preclinical cancer models.

bioRxiv · May 18, 2025 · PreprintCancer Biology